DEPDC1 and urinary bladder carcinoma: Recently, a DEPDC1-derived short peptide vaccine has demonstrated promising efficacy in preventing bladder cancer recurrence in a phase I/II clinical trial (Murahashi et al., 2016; Obara et al., 2017).